| Literature DB >> 25741473 |
Michael A Liss1, Nathan S White2, J Kellogg Parsons1, Natalie M Schenker-Ahmed2, Rebecca Rakow-Penner2, Joshua M Kuperman2, Hauke Bartsch2, Hyung W Choi2, Robert F Mattrey2, William G Bradley2, Ahmed Shabaik3, Jiaoti Huang4, Daniel J A Margolis5, Steven S Raman5, Leonard S Marks6, Christopher J Kane1, Robert E Reiter6, Anders M Dale7, David S Karow2.
Abstract
PURPOSE: We evaluate a novel magnetic resonance imaging (MRI) technique to improve detection of aggressive prostate cancer (PCa).Entities:
Keywords: Gleason score; MRI imaging; cellularity; prostate; prostate cancer
Year: 2015 PMID: 25741473 PMCID: PMC4330697 DOI: 10.3389/fonc.2015.00030
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
MRI scan parameters for prostate MRI protocol at 3T.
| Pulse sequence | Parameters |
|---|---|
| T2 | Axial 3D TSE T2 (Siemens SPACE), TR/TE 3800-5040/101, ETL 13, 14 cm FOV, 256 × 256 matrix, 1.5 mm contiguous slices |
| Diffusion-weighted (standard) | echoplanar, TR/TE 3900/60, 21 × 26 cm FOV, 130 × 160 matrix, 3.6 mm slices, 4 NEX, |
| T1 dynamic perfusion imaging | Siemens TWIST, TR/TE 3.9/1.4 ms, 12° flip angle, 26 × 26 cm FOV, 160 × 160 matrix, 3.6 mm slices, 4.75 s/acquisition over 6 minutes with 15 s injection delay, image analysis using iCAD Versavue |
| Restriction spectrum imaging | Spin echo EPI, TR/TE 5500/137, 26 cm × 26 cm FOV, 128 × 96 matrix, 3.6 mm slices, 30 directions at each |
Demographics: perioperative demographics for 28 patients who underwent MRI with an endorectal coil and subsequently underwent radical prostatectomy.
| Age | Race | BMI | PSA | Clinical Stage | Biopsy Gleason | Positive cores | Maximum percent cancer % | Imaging criteria | Pathologic Gleason | Pathologic stage |
|---|---|---|---|---|---|---|---|---|---|---|
| 63 | White | 20.1 | 7 | T1c | 3 + 4 | 3 of 15 | 30 | 4 | 3 + 3 | T2 |
| 61 | White | 31.4 | 5.8 | T1c | 4 + 3 | 4 of 12 | 85 | 5 | 3 + 4 | T3b |
| 55 | White | 29.3 | 2.8 | T1c | 3 + 5 | 4 of 12 | 90 | 3 | 3 + 4 | T3a |
| 71 | White | 29.7 | 7.3 | T2 | 3 + 3 | 9 of 19 | 60 | 3 | 3 + 4 | T2 |
| 59 | White | 31.4 | 4.43 | T2 | 3 + 3 | 4 of 12 | 33 | 3 | 3 + 4 | T2c |
| 61 | White | 21.4 | 9.2 | T2 | 3 + 3 | 6 of 15 | 30 | 4 | 3 + 4 | T2b |
| 68 | White | – | 6.7 | T1c | 3 + 4 | 10 of 12 | 70 | 3 | 3 + 4 | T2c |
| 55 | White | 27.5 | 4.7 | T1c | 3 + 4 | 6 of 16 | 70 | 3 | 3 + 4 | T2b |
| 64 | White | 23.1 | 5.8 | T1c | 3 + 4 | 1 of 12 | 30 | 2 | 3 + 4 | T2c |
| 61 | Other | 26 | 3.4 | T1c | 3 + 4 | 6 of 13 | 95 | 3 | 3 + 4 | T2c |
| 60 | Unknown | 25.5 | 6 | T1c | 3 + 3 | 3 of 12 | – | 3 | 3 + 4 | T2 |
| 61 | White | 29.8 | 6.6 | T1c | – | – | – | 4 | 3 + 4 | T2 |
| 65 | Unknown | 29 | 5.4 | T2 | 3 + 4 | 2 of 14 | 45 | 2 | 3 + 4 | T2 |
| 50 | White | 31.2 | 8.9 | T1c | 3 + 4 | 2 of 12 | 20 | 4 | 3 + 4 | T2 |
| 53 | White | 22.7 | 3.9 | T1c | 4 + 3 | 3 of 8 | 15 | 2 | 3 + 4 | T3a |
| 44 | White | 26.6 | 2.8 | T1c | 3 + 4 | 4 of 16 | 70 | 3 | 3 + 4 | T2a |
| 58 | White | 32.7 | 3.8 | T1c | 3 + 4 | 6 of 12 | 70 | 3 | 3 + 4 | T2c |
| 53 | Asian | 16.9 | 5.5 | T1c | 3 + 4 | 3 of 12 | 15 | 4 | 3 + 4 | T2 |
| 62 | African American | 25.1 | 4.8 | T1c | 4 + 3 | 2 of 12 | 70 | 0 | 4 + 3 | T2a |
| 65 | White | 38.5 | 5.8 | T2 | 4 + 3 | 5 of 12 | 88 | 5 | 4 + 3 | T3a |
| 64 | White | 26.9 | 4.2 | T1c | 3 + 5 | 12 of 12 | 94 | 5 | 4 + 3 | T3a |
| 56 | Other | 28 | 11.5 | T1c | 3 + 4 | multiple | 50 | 4 | 4 + 3 | T3a |
| 67 | White | 30.4 | 5.1 | T1c | 3 + 4 | 5 of 13 | 25 | 4 | 4 + 3 | T3a |
| 71 | White | 28.4 | 12.8 | T1c | 4 + 3 | – | – | 5 | 4 + 3 | T3a |
| 45 | African American | 23.5 | 6.5 | T1c | 4 + 3 | 9 of 16 | 80 | 1 | 4 + 4 | T2c |
| 65 | White | 30.1 | 8.2 | T1c | 5 + 4 | – | 55 | 4 | 4 + 5 | T3b |
| 62 | White | 25.8 | 4.6 | T2 | 4 + 5 | 5 of 15 | 50 | 4 | 4 + 5 | T2 |
| 70 | Filipino | 35.5 | 7.5 | T2 | 4 + 3 | 9 of 12 | 90 | 3 | 4 + 5 | T3a |
Figure 1Representative images showing RSI . The last column displays the whole-mount pathology with the corresponding cancer region of interest circled in black. The star in the top right pathologic figure represents the pattern 3 + 3 prostate cancer while the other lesions are 4 + 3. White arrowheads in the higher-grade patients show areas of signal void, which could be interpreted as false positives on the ADC maps.
Figure 2RSI . The x-axis demonstrates the pathological Gleason scores in increasing levels of aggressiveness from left to right. Each data point represents one region of interest corresponding to a location on the whole-mount prostatectomy specimen contoured by a GU pathologist.
Univariable analysis: restriction spectrum imaging (RSI) .
| Sample size method | Means | Statistical test | |||
|---|---|---|---|---|---|
| Mean (standard error) | |||||
| 64 | Restricted spectrum imaging (RSI) | 97.7 | <0.001 | ||
| Benign | 0.65 (0.12) | ||||
| Primary Gleason 3 | 2.4 (0.61) | ||||
| Primary Gleason 4 | 2.9 (0.51) | ||||
| 64 | Apparent diffusion coefficient (ADC) | 13.9 | <0.001 | ||
| Benign | 1680 (428) | ||||
| Primary Gleason 3 | 1237 (425) | ||||
| Primary Gleason 4 | 967 (221) | ||||
| 36 | Restricted spectrum imaging (RSI) | 34 | 0.5 | 2.22 | 0.033 |
| 36 | Apparent diffusion coefficient (ADC) | 34 | 269 | 1.81 | 0.079 |
The top half of the table uses ANVOA analysis to determine differences in detection comparing benign vs. primary Gleason 3 vs. Primary Gleason 4 prostate cancer. The bottom half of the table only compares Gleason 3 vs. 4 cancers with a .
.
.
Figure 3Box plot of RSI .
Multivariable analysis: restriction spectrum imaging (RSI) .
| Sample size method | Parameter coefficient | McFadden’s | |||
|---|---|---|---|---|---|
| 64 | Restricted spectrum imaging (RSI) | <0.001 | 0.613 | ||
| Benign | 0 | ||||
| Primary Gleason 3 | 9.5 (−1.9 to 17.0) | 0.014 | |||
| Primary Gleason 4 | 15.8 (6.4–25.2) | 0.001 | |||
| 64 | Apparent diffusion coefficient (ADC) | <0.001 | 0.202 | ||
| Benign | 0 | ||||
| Primary Gleason 3 | 1.7 (−3.2 to 6.7) | 0.483 | |||
| Primary Gleason 4 | 4.5 (−0.5 to 9.6) | 0.076 | |||
| 36 | Restricted spectrum imaging (RSI) | 5.1 | 10.3 (1.4–78.0) | 0.024 | |
| 36 | Apparent diffusion coefficient (ADC) | 3.3 | 0.9 (0.9–1.00) | 0.069 | |
The top half of the table uses ordinal logistic regression analysis to determine differences in detection comparing benign vs. primary Gleason 3 vs. Primary Gleason 4 prostate cancer (Log Odds). The bottom half of the table only compares Gleason 3 vs. 4 cancers to determine with binary logistic regression (Odds Ratio).
.
.
.